NCT05764395 2024-10-10Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 InhibitorsVanderbilt-Ingram Cancer CenterPhase 2 Suspended29 enrolled